Purpose: To link optic nerve (ON) structural integrity to clinical markers of glaucoma using 30 advanced, semi-automated diffusion weighted imaging (DWI) tractography methods in human 31 glaucoma patients. 32
R 2 = 0.63) and ON FA predicted perceptual deficits (visual field index [VFI]) (F(1,10) = 15.308, 48 p < 0.005, R 2 = 0.52). 49
Introduction 54
Vision loss is a major cause of disability worldwide that is particularly common among 55 the elderly, conferring a greater risk of injury and diminished quality of life [1] [2] . Glaucoma is 56 the leading cause of irreversible vision loss worldwide and is projected to affect nearly 80 57 million individuals by 2020 [3] . It is clinically defined by characteristic patterns of visual field 58 impairment and optic nerve (ON) damage [4] . There is growing evidence that glaucoma may be 59 a neurodegenerative condition. Recent studies suggest that the pathogenesis of glaucoma bears 60 similarities to that of Alzheimer's disease, Parkinson's, and amyotrophic lateral sclerosis (ALS) 61
[6]. Thus, research seeking to understand the possible underlying neurodegenerative processes 62 associated with glaucoma may help guide the development of more robust treatment paradigms 63 and have applications for improving our understanding of other neurodegenerative diseases. In 64 addition, current glaucoma treatments are limited to the reduction of intraocular pressure (IOP) 65 to prevent progressive visual field loss. However, many patients continue to lose vision despite 66 treatment, and no treatments are available to reverse damage that has already occurred to the 67 visual system [4] . Therefore, the development of robust methods enabling earlier diagnosis and 68 more precise quantification of disease progression are essential to limiting glaucomatous damage 69 and improving patient outcomes. 70 MRI-based in vivo human studies using voxel-based morphometry (VBM) and diffusion 71 tensor imaging (DTI) to explore gray-and white-matter cortical changes associated with 72 glaucoma have shown reduced gray-matter (GM) volume in late stages of the disease, along with 73 significant rarefaction along the optic radiations [7] [8] [9] . While these results are consistent with 74 animal models and post-mortem pathological studies of human subjects [10] , there is a need for 75 more precise evaluation of neurological changes, particularly at the level of the ON substantially since the publication of these studies, and there is an opportunity to investigate and 95 validate methods that rely on semi-automated techniques to assess the ON using dMRI.
Recent diffusion-weighted imaging (DWI) based probabilistic tractography methods have 97
been developed that can more precisely evaluate white-matter changes in the human visual 98 system. These methods have demonstrated reduced white matter integrity in patients with 99 amblyopia [20] . In this study, we apply this technique to patients with asymmetric glaucomatous 100 optic neuropathy in each eye to evaluate DWI methods as a diagnostic tool for visual disorders, the ONs to be isolated using probabilistic tractography. This provides a unique opportunity to 106 quantify changes across the entire length of the ONs in glaucoma patients. Further, we 107 purposefully selected patients with asymmetric glaucomatous ON damage to allow for within-108 subjects comparisons of ON properties, quantifying differences in eyes with "advanced" versus 109 "mild" glaucoma as defined by the American Academy of Ophthalmology [24] . 110
We used an advanced DWI tractography method to identify and analyze the ONs of six 111 asymmetric glaucoma patients and six controls. Using both within-subject analyses and 112 comparison to controls, we evaluated structural changes in the ONs associated with glaucoma. 113 Furthermore, we assessed the relationship between these MRI-based neural measures, clinical 114 measures of ON and retinal integrity (e.g. vertical cup-to-disc ratio and average peripapillary 115 retinal nerve fiber layer thickness), and perceptual measures (e.g. visual field index). had Snellen best-corrected visual acuity of 20/20 or better and had no prior medical history of 138 neurologic or ocular pathology other than refractive error. Eye dominance was determined as 139 follows: subjects were instructed to form a small aperture using both hands (right and left hands 140 overlapping so a small opening is formed with the inner sides of the palms and thumbs) and to 141 fixate on a distant object through that opening with both eyes open. Without moving their head 142 or hands, subjects were then instructed to close their left eye and were asked whether or not they 143 could still see the object. This same task was repeated with the right eye closed. The eye with 144 which they could see the fixation target was recorded as the "dominant" eye. Ocular dominance 145 was successfully determined for 6/6 control subjects. with 500,000 seeds and a maximum of 5,000,000 fibers. A modified white-matter mask 196 generated using mrVista was used to constrain fibers to the brain while still allowing CSDs to be 197 fit within the nasal cavity, enabling detection of the ONs. Final pathways were restricted to fibers 198 passing between the specified ROIs, omitting any spurious results. 199 Fibers were overlaid on the anatomical T1 volume and any fibers that were found to be 203 anatomically implausible were manually removed. Pathways from all 12 participants were 204 processed using the same AFQ cleaning parameters and were manually refined by the same 205 operator (N.M.) ( Fig. 1) . 206 
Fiber Cleaning

Analysis
233
A combination of within-and between-groups analyses were conducted to evaluate the 234 structural white-matter changes associated with glaucoma-related vision damage. All six 235 asymmetric glaucoma patients had one eye with no or early glaucomatous visual field defects 236 ("mild") and one eye with moderate or advanced glaucomatous visual field defects ("advanced") 237
[24]. Within-subjects, diffusion-tensor properties were compared between the "advanced" and 238 "mild" eyes. Between-subjects, the ratios of "advanced" / "mild" ON FA in glaucoma patients were compared to non-dominant/dominant ratios in controls. This design minimized the possible 240 effect of global changes in white-matter properties as a result of age. 241
To facilitate these comparisons and normalize pathway lengths, 100 samples were taken 242 along the length of each pathway such that 100 average MD, FA, RD, and AD values were 243 available for each pathway in each of the two groups (glaucoma patients and control subjects). 244
These values were generated for each cross-section using a Gaussian-weighted average, where 245 the calculated "core" of each pathway was selectively weighted over the outlying fibers. From 246 these 100 samples, the central 80 were retained for further analysis to reduce the risk of 
Results
262
Selection of Clinical Measures of Structure and Function
263
As expected, we identified strong correlations between vCD and RNFL (F(1,10) = 264 229.17, p = 3.20e-8, R 2 = 0.98), vCD and VFI (F(1,10) = 15.662, p = 0.0027, R 2 = 0.64), and 265 RNFL and VFI (F(1,10) = 24.228, p = 0.00060, R 2 = 0.76) (Fig 3) . These measures quantify the 266 anticipated correlations between clinical measures of structural and functional glaucomatous 267 optic nerve damage in our patient sample. 
Diffusion Magnetic Resonance Imaging
278
ON white-matter pathways were successfully identified and refined in 6/6 glaucoma 279 patients and 6/6 controls. All pathways appeared to be anatomically plausible after cleaning and 280
were amenable to within-subjects and group-wise comparisons. A significant difference in mean 281 55.442, p1 = 2.20e-5; F2(1,10) = 18.382, p2 = 0.0016; F3(1,10) = 11.322, p3 = 0.0072), along with 283 a significant difference across the middle 80% of samples (F(1,10) = 55.474, p = 2.19e-5) (Fig  284   4 ). In the same pathway, a significant difference in average MD was noted in 1/8 bins (F(1,10) = 285 10.885, p = 0.0080). For RD, we found a significant difference in 3/8 bins (F1(1,10) = 15.87, p1 = 286 0.0026; F2(1,10) = 4.974, p2 = 0.0498; F3(1,10) = 5.687, p3 = 0.038), along with a significant 287 difference across the middle 80% (F(1,10) = 5.118, p = 0.047). No significant difference in AD 288 was found (all p > 0.05). Our subsequent analyses focus on ON FA because of the magnitude 289 and reliability of the effect (compared to MD and RD). 
301
To more precisely characterize the nature of these within-subject effects, we compared 302 the FA ratios of advanced/mild ONs in glaucoma patients to non-dominant/dominant ONs in 303 controls. We found selective FA reductions in the "advanced" ONs of glaucoma patients. As 304 expected, there were no significant differences between non-dominant and dominant ON FA 305 values in control subjects. We found a significant difference between the ON FA ratios of 306 glaucoma patients compared to controls in a LME model including group and age as fixed 307 factors (F(1,9) = 20.276, p = 0.0015) ( Fig 5) . 
311
Comparison of optic nerve fractional anisotropy ratios (%) in glaucoma patients (green) and controls 312 (blue). Glaucoma patient ratios were calculated for "advanced" / "mild" optic nerve fractional anisotropy, 313 and control subject ratios were calculated for non-dominant/dominant optic nerve fractional anisotropy.
314
Mean ratios are indicated by the bold lines, with standard error denoted by the surrounding box. We 315 found a significant difference between fractional anisotropy ratios in glaucoma patients versus controls (p 316 = 0.0015).
318
Relating dMRI to Clinical Measures in Glaucoma
319
Reductions in ON FA were found to correlate with clinical measures of glaucoma (vCD, 320 RNFL, and VFI). We found that vCD predicted ON FA (F(1,10) = 11.061, p = 0.0077, R 2 = 321 0.66), RNFL predicted ON FA (F(1,10) = 11.477, p = 0.0069, R 2 = 0.63), and ON FA in turn 322 predicted VFI (F(1,10) = 15.308, p = 0.0029, R 2 = 0.52) ( Fig 6) . Thus, dMRI measures of white 323 
328
Vertical cup-to-disc ratio predicts optic nerve fractional anisotropy (p = 0.0077, R 2 = 0.66). (B) Average 329 retinal nerve fiber layer thickness predicts optic nerve fractional anisotropy (p = 0.0069, R 2 = 0.63). (C) Optic nerve fractional anisotropy predicts visual field index (p = 0.0029, R 2 = 0.52). Correlations within 331 individual patients are indicated by each solid colored line, with closed points marking eyes with 332 "advanced" glaucoma and open points marking eyes with "mild" glaucoma. A least-squares regression 333 estimate is indicated by the dashed line.
335
Discussion
336
We assessed the utility of probabilistic DWI tractography in correlating neural and 337 clinical measures of ON damage in patients with asymmetric glaucoma and normal controls. We 338 isolated the ON white-matter pathway in 6/6 glaucoma patients and 6/6 controls. We combined 339 AP and PA phase-encoded dMRI volumes to recover from imaging distortions caused by the 340 adjacent nasal cavities. To our knowledge, this is the first probabilistic tractography study to 341 successfully isolate the ONs in visually-impaired patients. Previous work relied largely on 342 manual ON segmentation or ROI-based analyses, while our methodology allows the entire ON to 343 be identified with minimal manual operator input. This technique increases the efficiency of data 344 collection and reduces the risk of operator error. We correlated clinical measures of ON structure 345 and function (i.e. vCD, RNFL, and VFI) with dMRI measures of ON integrity (i.e. FA, MD, RD, 346 and AD). Our methods sample diffusion measures along the entire length of the ON (rather than 347 small targeted regions) and provides a more comprehensive account of dMRI measures of 348
disease. 349
We found significant differences in average FA, MD, and RD of ONs with "advanced" 350 versus "mild" glaucoma. These trends (smaller FA and greater MD and RD in "advanced" ONs) 351 indicate reduced integrity of the visual system consistent with clinical measures of glaucoma 352 severity. Our findings are mostly consistent with earlier studies, which showed general trends of 353 decreasing FA and increasing MD with increasing glaucoma severity [14-19]. However, there 354 was a significant difference in radial, but not axial diffusivity, which would suggest that 355 glaucoma predominantly impacted myelination rather than axonal degeneration of ONs with 356 advanced glaucoma. This result differs from previous work, where changes were noted in both 357 RD and AD [16] . This discrepancy may be the result of differences in diffusion sequence 358 parameters but is most likely the result of our small sample size. 359
To minimize the impact of the small sample size and the difference in mean age between 360 our glaucoma patients and controls in this study, we primarily relied on within-subjects 361 comparisons. Through ratio comparison of ON FA ratios in glaucoma patients to controls, we 362 determined that these structural changes were not global changes in the ONs of glaucoma 363 patients, but rather unilateral changes in the "advanced" glaucomatous eyes. 364
Lastly, we examined the correlation between clinical glaucoma measures (vCD, RNFL, 365 and VFI) and dMRI neural measures (ON FA). We found that vCD and RNFL were correlated 366 with ON FA and that ON FA was predictive of VFI. Thus, our analysis confirms and quantifies 367 correlations between measures of glaucoma-related damage between neural (ON FA), structural 368 (vCD), retinal (RNFL), and functional (VFI) measures. 369
In summary, we correlated neural DWI measures and clinical glaucoma measurements in 370 patients with asymmetric glaucoma damage. Our results using current dMRI methods agree with 371 previous studies using older techniques and validate probabilistic tractography methods that 372 assess deficits in the visual pathways of glaucoma patients. Future larger, prospective studies 373 may evaluate dMRI as a possible diagnostic tool for glaucoma evaluation. In addition, studies 374 quantifying the relationship between neural and clinical measures longitudinally may determine 375 whether these methods may be useful for monitoring glaucoma progression and treatment 376 efficacy. 377
